GlassScriptPhysician profile
Andrew R Beardsley
NPI 1881855948
$2,548.47
in general payments reported to CMS, 2019-2025
41 companies · $999 in 2025
The $999 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2021: $150 · 2022: $252 · 2023: $456 · 2024: $534 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,799.97 |
| Education | $189.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $368.17 | 2021-2025 | |
| Janssen Biotech, INC. | $298.04 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $242.79 | 2022-2025 | Enhertu, Imfinzi, Lynparza |
| Medtronic USA, INC. | $157.08 | 2019 | |
| Pfizer INC. | $155.59 | 2021-2025 | |
| Incyte Corporation | $142.13 | 2022-2025 | Jakafi |
| Merck Sharp & Dohme LLC | $139.87 | 2021-2025 | Keytruda, Welireg, Keytruda Qlex |
| Abbvie INC. | $93.72 | 2021-2025 | |
| Glaxosmithkline, LLC. | $63.32 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Array Biopharma INC | $62.00 | 2023-2025 | Lorbrena, Braftovi, Mektovi |
| Mirati Therapeutics, INC. | $50.65 | 2023 | Krazati |
| Seagen INC. | $49.23 | 2022-2023 | Tukysa |
| Kyowa Kirin, INC. | $44.98 | 2022-2024 | Poteligeo |
| Beone Medicines USA, INC. | $43.14 | 2025 | Tevimbra, Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $41.64 | 2024-2025 |
Show all 39 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Beardsley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.